Matches in Wikidata for { <http://www.wikidata.org/entity/Q82903437> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q82903437 description "artículu científicu espublizáu n'avientu de 2011" @default.
- Q82903437 description "im Dezember 2011 veröffentlichter wissenschaftlicher Artikel" @default.
- Q82903437 description "scientific article published on 01 December 2011" @default.
- Q82903437 description "wetenschappelijk artikel" @default.
- Q82903437 description "наукова стаття, опублікована в грудні 2011" @default.
- Q82903437 name "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 name "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 type Item @default.
- Q82903437 label "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 label "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 prefLabel "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 prefLabel "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (O" @default.
- Q82903437 P1433 Q82903437-817C02BE-3D31-4E72-91A3-9B62AFF105F1 @default.
- Q82903437 P1476 Q82903437-C57A7E48-C61E-459A-B38E-BB3C613468C0 @default.
- Q82903437 P2093 Q82903437-8E12B86F-809C-4377-91C6-F164FEA78F9A @default.
- Q82903437 P304 Q82903437-D491B7E8-687C-4D2D-9FC8-93019658D2D7 @default.
- Q82903437 P31 Q82903437-3171002C-1AA4-4DF6-ACD8-5E68A6897584 @default.
- Q82903437 P356 Q82903437-79FD440C-2336-42DB-AA98-3F81F703FBC5 @default.
- Q82903437 P433 Q82903437-B622B595-0497-45B9-8323-E97154E215B5 @default.
- Q82903437 P478 Q82903437-E14A1F69-9ACF-406B-AC7B-C669DB2FC62C @default.
- Q82903437 P577 Q82903437-393A53AD-0678-4959-9509-A91DA12F56DC @default.
- Q82903437 P698 Q82903437-E929B415-5F68-48AB-84FF-842442A04D8A @default.
- Q82903437 P921 Q82903437-0A3A0B1E-E3BC-4F35-AB11-938D2DE869FD @default.
- Q82903437 P921 Q82903437-4D847C73-E08D-4538-8981-02472B86C52B @default.
- Q82903437 P921 Q82903437-599195E4-500C-4C12-9DE4-C31988702896 @default.
- Q82903437 P356 S00120-011-2768-3 @default.
- Q82903437 P698 22159705 @default.
- Q82903437 P1433 Q27713718 @default.
- Q82903437 P1476 "[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)]" @default.
- Q82903437 P2093 "H Rexer" @default.
- Q82903437 P304 "1617-1618" @default.
- Q82903437 P31 Q13442814 @default.
- Q82903437 P356 "10.1007/S00120-011-2768-3" @default.
- Q82903437 P433 "12" @default.
- Q82903437 P478 "50" @default.
- Q82903437 P577 "2011-12-01T00:00:00Z" @default.
- Q82903437 P698 "22159705" @default.
- Q82903437 P921 Q2501186 @default.
- Q82903437 P921 Q269829 @default.
- Q82903437 P921 Q412415 @default.